The reduction in metabolic plasticity via intermittent fasting to limit glucose availability (and therefore glycolysis) and metformin (an inhibitor of oxidative phosphorylation) led to decreases in tumor growth in mice with melanoma xenografts via lowered MCL1 expression [122]. The gene discussed is MCL1; the disease is melanoma.